Differentiation therapy of myelodysplastic syndromes: fact or fiction?

Br J Haematol. 1998 Sep;102(5):1124-38. doi: 10.1046/j.1365-2141.1998.00881.x.
No abstract available

Publication types

  • Review

MeSH terms

  • Acetamides / therapeutic use
  • Amifostine / therapeutic use
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Arginine / therapeutic use
  • Azacitidine / therapeutic use
  • Butyrates / therapeutic use
  • Cholecalciferol / therapeutic use
  • Cytarabine / therapeutic use
  • Harringtonines / therapeutic use
  • Hematopoietic Cell Growth Factors / therapeutic use
  • Heme / therapeutic use
  • Homoharringtonine
  • Humans
  • Interferons / therapeutic use
  • Myelodysplastic Syndromes / therapy*
  • Retinoids / therapeutic use

Substances

  • Acetamides
  • Antineoplastic Agents
  • Butyrates
  • Harringtonines
  • Hematopoietic Cell Growth Factors
  • Retinoids
  • Cytarabine
  • Cholecalciferol
  • Heme
  • Homoharringtonine
  • Interferons
  • Arginine
  • hexamethylene bisacetamide
  • Amifostine
  • Azacitidine
  • heme arginate